AC Immune SA (ACIU) - Financial and Strategic SWOT Analysis Review

October 2021 | 51 pages | ID: A45F61029CCEN
GlobalData

Abstracts

AC Immune SA (ACIU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AC Immune SA (AC Immune) is a clinical-stage biopharmaceutical company that discovers, designs and develops proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms: SupraAntigen and Morphomer. Its technology platforms help the company design, discover and develop antibodies, small molecules and vaccines. AC Immune’s product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company’s lead product candidate, crenezumab, is a monoclonal antibody that targets abeta in cognitive healthy individuals who are at risk of developing familial Alzheimer’s Disease (fAD). AC Immune is headquartered in Lausanne, Switzerland.

AC Immune SA Key Recent Developments

Aug 04,2021: AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Apr 28,2021: AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update
Mar 31,2021: AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors
Mar 23,2021: AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
Feb 24,2021: AC Immune to present new data from Alpha-Synuclein and TDP-43 programs at the AD/PD 2021 virtual conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

AC Immune SA - Key Facts
AC Immune SA - Key Employees
AC Immune SA - Key Employee Biographies
AC Immune SA - Major Products and Services
AC Immune SA - History
AC Immune SA - Company Statement
AC Immune SA - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
AC Immune SA - Business Description
R&D Overview
AC Immune SA - Corporate Strategy
AC Immune SA - SWOT Analysis
SWOT Analysis - Overview
AC Immune SA - Strengths
AC Immune SA - Weaknesses
AC Immune SA - Opportunities
AC Immune SA - Threats
AC Immune SA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
AC Immune SA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 04, 2021: AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Apr 28, 2021: AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update
Mar 31, 2021: AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors
Mar 23, 2021: AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
Feb 24, 2021: AC Immune to present new data from Alpha-Synuclein and TDP-43 programs at the AD/PD 2021 virtual conference
Feb 17, 2021: AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference
Nov 20, 2020: Immunotherapy Pioneer Prof. Carl H. June joins AC Immune’s Board of Directors
Nov 18, 2020: Neurologist and psychiatrist Prof. Johannes Rolf Streffer, MD joins AC Immune as chief medical officer
Nov 13, 2020: AC Imune reports Q3 2020 financial results and provides business update
Sep 11, 2020: AC Immune to showcase Anti-Tau Portfolio at H.C. Wainwright 22nd Annual Global Investment Conference

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

AC Immune SA, Key Facts
AC Immune SA, Key Employees
AC Immune SA, Key Employee Biographies
AC Immune SA, Major Products and Services
AC Immune SA, History
AC Immune SA, Key Competitors
AC Immune SA, Ratios based on current share price
AC Immune SA, Annual Ratios
AC Immune SA, Annual Ratios (Cont...1)
AC Immune SA, Interim Ratios
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
AC Immune SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

AC Immune SA, Performance Chart (2016 - 2020)
AC Immune SA, Ratio Charts
AC Immune SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
AC Immune SA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021